Adaptive randomization of veliparib-carboplatin treatment in breast cancer
Antineoplastic Combined Chemotherapy Protocols
Triple Negative Breast Neoplasms
The process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer. (Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).